SEARCH

SEARCH BY CITATION

References

  • 1
    Rowley SD, Zuehlsdorf M, Braine HG, et al. CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 1987; 70:271275.
  • 2
    Emminger W, Emminger-Schmidmeier W, Hocker P, et al. Myeloid progenitor cells (CFU-GM) predict engraftment kinetics in autologous transplantation in children. Bone Marrow Transplant 1989; 4:415420.
  • 3
    Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87:825831.
  • 4
    Bensinger WI, Appelbaum FR, Rowley S, et al. Factors influencing collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995 (in press).
  • 5
    Bender JG, To LB, Williams S, et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematotherapy 1992; 1:329341.
  • 6
    Fernandez HF, Noto TA, Morrell L, et al. Early engraftment of mobilized autologous peripheral blood progenitor cells collected by large volume leukapheresis. Blood 1994; 84(suppl 1):365a.
  • 7
    Rybka WB, Kiss JE, Lister J, et al. Graft CD34+ cell content predicts engraftment following allogeneic and autologous hematopoietic stem cell transplantation. Blood 1994; 84(suppl 1):338a.
  • 8
    Pecora AL, Brochstein JA, Jennis A, et al. Total CD34+ cell content and CD34+CD33 subset predict time to neutrophil and platelet engraftment and hospital discharge in patients following high-dose chemotherapy with primed peripheral blood progenitor cells. Blood 1994; 84(suppl 1):342a.
  • 9
    Weaver CH, Birch R, Schwartzberg L, et al. CD34 content of peripheral blood progenitor cells (PBPC) is the single most powerful predictor of recovery kinetics in patients receiving myeloablative high-dose chemotherapy and PBPC infusion. Blood 1994; 84(suppl 1):1388a.
  • 10
    Smith R, Sweetenham JW. A mononuclear cell dose of 3 × 108/kg is sufficient to predict early multilineage engraftment in patients undergoing high dose therapy and transplantation with cryopreserved peripheral blood progenitor cells for malignant lymphoma. Blood 1994; 84(suppl 1):364a.
  • 11
    Schwartzberg L, Birch R, Blanco R, et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11:369374.
  • 12
    Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588596.
  • 13
    Schiller G, Rosen L, Vescio R, et al. Threshold dose of autologous CD34 positive peripheral blood progenitor cells required for engraftment after myeloablative treatment for multiple myeloma. Blood 1994; 84(suppl 1):813a.
  • 14
    Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83:37873794.
  • 15
    Spencer V, Smith J, Kulkarni S, et al. Does transplantation of a high number of CD34 cells predict more rapid engraftment following high-dose chemotherapy. Proc ASCO 1992; 11:131a.
  • 16
    Mortimer J, Hendricks D, Goodnough LT, et al. Pheresis of peripheral blood progenitor cells directed by CD34 counts. Proc ASCO 1993; 12:467a.
  • 17
    Reid CDL, Kirk A, Muir J, et al. The recovery of circulating progenitor cells after chemotherapy in AML and ALL and its relation to the rate of bone marrow regeneration after aplasia. Br J Haematol 1989; 72:2127.
  • 18
    Cantin G, Marchand-LaRoche D, Bouchard MM, et al. Blood-derived stem cell collection in acute nonlymphoblastic leukemia: predictive factors for a good yield. Exp Hematol 1989; 17:991996.
  • 19
    Pettengell R, Morgenstern GR, Woll PJ, et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993; 82:37703777.
  • 20
    Ho AD, Gluck S, Germond C, et al. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993; 7:17381744.
  • 21
    Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77:400409.
  • 22
    Seong D, Anderson B, Korbling M, et al. Predicting parameters of successful peripheral blood stem cell (PBSC) collection after chemo/cytokine primed mobilization in relapsed Hodgkin's disease. Proc ASCO 1995; 14:951a.
  • 23
    Glaspy J, Chap L, Menchaca D, et al. Effect of prior chemotherapy on peripheral blood progenitor cell (PBPC) harvests in patients with breast cancer. Proc ASCO 1995; 14:943a.
  • 24
    Dreger P, Haferlach T, Eckstein V, et al. G-CSF mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87:609613.
  • 25
    Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Blood 1995; 85:16551658.
  • 26
    Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (Granulocyte colony-stimulating factor). Blood 1995; 85:16661672.
  • 27
    Elias AD, Ayash L, Anderson KC, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79:30363044.
  • 28
    Dreger P, Marquardt P, Haferlach T, et al. Effective mobilization of peripheral blood progenitor cells with Dexa-BEAM and G-CSF-timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993; 68:5:950957.
  • 29
    Bender JG, Williams SF, Myers S, et al. Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation. Bone Marrow Transplant 1992; 10:281285.
  • 30
    Hohaus S, Goldschmidt H, Ehrhardt R, et al. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus RHG-CSF. Exp Hematol 1993; 21:4:508514.
  • 31
    Passos-Coelho JL, Braine HG, Davis JM, et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 1995; 13:705714.
  • 32
    Sica S, Dimario A, Salutari P, et al. Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and G-CSF in patients with resistant lymphoma. Am J Hematol 1994; 46:1:1823.
  • 33
    Brugger W, Bross K, Frisch J, et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 1992; 79:11931200.
  • 34
    To LB, Shepperd M, Haylock DN, et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18:442447.
  • 35
    Kotasek D, Shepperd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9:1117.
  • 36
    Sutherland HJ, Eaves CJ, Lansdorp PM, et al. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. Blood 1994; 83:38083814.
  • 37
    Siena S, Bregni M, Bonsi L, et al. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors. Exp Hematol 1993; 21:12:15831590.
  • 38
    Klumpp TR, Mangan KF, Glenn LD, et al. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 1993; 12:337345.
  • 39
    Indovina A, Majolino I, Scime R, et al. High dose cyclophosphamide: stem cell mobilizing capacity in 21 patients. Leuk Lymphoma 1994; 14:1-2:7177.
  • 40
    Fennelly D, Bengala C, Schneider J, et al. Peripheral blood progenitor cell mobilization using Taxol® in combination with cyclophosphamide and G-CSF; quantitation and correlation of CD34+ cell count, colony-forming-unit-granulocyte-macrophage (CFU-GM) and mononuclear cell count. Blood 1994; 84(suppl 1):409a.
  • 41
    Demirer T, Buckner CD, Bensinger WI, et al. Peripheral blood stem cell (PBSC) collections after Taxol®, cyclophosphamide and recombinant human granulocyte-colony stimulating factor (rhG-CSF). J Clin Oncol 1995; 13:17141719.
  • 42
    Raptis G, Tiersten A, Fennelly D, et al. The addition of paclitaxel (TXL) to high dose cyclophosphamide (CTX) + filgrastim (G-CSF) markedly enhances the mobilization of CD34+ peripheral blood progenitor cells (PBPC) in patients with responding metastatic breast cancer undergoing high dose chemotherapy. Proc ASCO 1995; 14:919a.
  • 43
    Schwartzberg LS, Birch R, Hazelton B, et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte-colony stimulating factor. J Hematotherapy 1992; 1:317327.
  • 44
    Haas R, Ehrhardt R, Witt B, et al. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma. Bone Marrow Transplant 1993; 12:643649.
  • 45
    Hogge DE, Eaves CJ, Sutherland HJ, et al. Administration of IL-3 with GM-CSF after high-dose cyclophosphamide mobilizes blood progenitors which enhance platelet recovery following autologous transplantation. Blood 1994; 84(suppl 1):412a.
  • 46
    D'Hondt V, Guillaume T, Humblet Y, et al. Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study. Bone Marrow Transplant 1994; 13:261264.
  • 47
    Ravagnani F, Notti P, Siena S, et al. Clinical application of growth factors for collection of circulating hematopoietic progenitors in breast cancer patients treated with high-dose cyclophosphamide. Int J Artif Organs 1993; 5:3538.
  • 48
    Bishop MR, Anderson JR, Jackson JD, et al. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994; 83:610616.
  • 49
    Bensinger WI, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81:31583163.
  • 50
    Bolwell BJ, Fishleder A, Andresen SW, et al. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bone Marrow Transplant 1993; 12:609614.
  • 51
    Bacigalupo A, Piaggio G, Podesta MT, et al. Collection of peripheral blood hematopoietic progenitors (PBHP) from patients with severe aplastic anemia (SAA) after prolonged administration of granulocyte colony-stimulating factor. Blood 1993; 82:14101414.
  • 52
    Nademanee A, Sniecinski I, Schmidt GM, et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12:21762186.
  • 53
    Hénon PR, Becker M. Cytokine enhancement of peripheral blood stem cells. STEM CELLS 1993; 11:6571.
  • 54
    Sheridan W, Begley G, Juttner C, et al. Effect of different doses and schedules of filgrastim on mononuclear cell and PBPC collections and hematopoietic recovery after high dose chemotherapy and infusion of filgrastim mobilized PBPC without bone marrow. ASH 1992:1315a.
  • 55
    Glaspy J, McNiece I, LeMaistre F, et al. Effects of stem cell factor (rhSCF) and filgrastim (rhG-CSF) on mobilization of peripheral blood progenitor cells (PBPC) and on hematologic recovery post-transplant: early results from a phase I/II study. Proc ASCO 1994; 13:76a.
  • 56
    Zeller W, Cassens U, Stockschlader M, et al. Higher dose of G-CSF increases yield of mobilized CD34+ cells. Blood 1994; 84(suppl 1):413a.
  • 57
    Hocker P, Geissler K, Kurz M, et al. Potentiation of GM-CSF or G-CSF induced mobilization of circulating progenitor cells by pretreatment with IL-3 and harvest by apheresis. Int J Artif Organs 1993; 5:2529.
  • 58
    Willerford DM, Preffer F, McAfee S, et al. Mobilization of early and late hematopoietic precursors using GMCSF, GCSF or combined GMCSF and GCSF following chemotherapy. Blood 1994; 84(suppl 1):350a.
  • 59
    Spitzer G, Mathews M, Dunphy F, et al. Are growth factors (GF) combinations superior to G-CSF alone for mobilization of peripheral blood stem cells (PBSC): a randomized study comparing G-CSF to G-CSF with GM-CSF for PBSC mobilization. Blood 1994; 84(suppl 1):415a.
  • 60
    Bishop MR, Vose JM, Bierman PJ, et al. Phase I trial of PIXY 321 for peripheral stem cell mobilization in patients with lymphoid malignancies. Exp Hematol 1994; 22:369a.
  • 61
    Brugger W, Bross KJ, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83:636640.
  • 62
    Brenner MK, Rill DR, Moen RC. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341:8586.
  • 63
    Ross AM, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82:26052610.
  • 64
    Vora AJ, Toh CH, Peel J, et al. Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br J Haematol 1994; 86:180182.
  • 65
    Gibson J, Pope B, Petersen A, et al. G-CSF stimulated PBSC harvests in myeloma contain immature malignant plasma cells. Blood 1994; 84(suppl 1):422a.
  • 66
    Brockstein B, Ross A, Hollingsworth K, et al. Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced breast cancer patients undergoing high-dose chemotherapy. Proc ASCO 1995; 14:975a.
  • 67
    Owen RG, Child JA, Rawson A, et al. Detection of contaminating cells in PBPC harvests and the efficacy of CD34 selection in patients with multiple myeloma. Blood 1994; 84(suppl 1):1392a.
  • 68
    Witzig TE, Gertz MA, Pineda AA, et al. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Blood 1994; 84(suppl 1):1393a.
  • 69
    Rill DR, Moen RC, Buschle M, et al. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood 1992; 79:26942700.
  • 70
    Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12:2836.
  • 71
    Vescio RA, Hong CH, Cao J, et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994; 84:32833290.
  • 72
    Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81:18831888.
  • 73
    Weaver CH, Buckner CD, Longin K, et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82:19811984.
  • 74
    Lane TA, Law P, Maruyama M, et al. Mobilization of peripheral blood stem cells in normal donors by G-CSF and GM-CSF: potential role in allogeneic marrow transplantation. Proc ASCO 1995; 14:2a.
  • 75
    Korbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85:16591665.
  • 76
    Oblon DJ, Paul S, Oblon MB, et al. Allogeneic peripheral blood stem cell transplants: preliminary results. Blood 1994; 84(suppl 1):366a.
  • 77
    Papayannopoulou TS, Nakamato B. Peripheralization of hematopoietic progenitors in primates treated with anti-VLA integrin. Proc Natl Acad Sci USA 1993; 90:93749378.